株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性腎臓病による貧血:疫学・患者ベースの市場予測・治療アルゴリズム・上市済みおよび開発中の薬剤の分析

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035

発行 Datamonitor Healthcare 商品コード 365170
出版日 ページ情報 英文 318 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
慢性腎臓病による貧血:疫学・患者ベースの市場予測・治療アルゴリズム・上市済みおよび開発中の薬剤の分析 Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035
出版日: 2018年07月17日 ページ情報: 英文 318 Pages
概要

新たなHIF阻害剤Roxadustatの投入によってバイオシミラーによるEpogenの侵食が相殺され、市場成長が推進される見通しです。

当レポートでは、慢性腎臓病による貧血治療薬の動向を調査し、市場の定義と概要、疾患の定義と診断、現在の治療オプション、処方動向、アンメットニーズ、主な上市済み製品のプロファイル、パイプラインの動向などをまとめています。

予測:慢性腎臓病による貧血

  • エグゼクティブサマリー
  • 市場概要・動向
  • 市場の定義・調査手法
  • Aranesp (ダルベポエチンアルファ)
  • Auryxia (クエン酸鉄)
  • DexFerrum (デキストラン鉄)
  • Epogen (エポエチンアルファ)
  • Feraccru (鉄トリマルトール)
  • Feraheme (フェルモキシトール)
  • Injectafer (カルボキシマルトース)
  • Mircera (メトキシポリエチレングリコールエポエチンベータ)
  • NeoRecormon (エポエチンベータ)
  • Roxadustat
  • Venofer (スクロース鉄)
  • プライマリーリサーチの手法

治療:慢性腎臓病による貧血

  • エグゼクティブサマリー
  • プライマリーリサーチの手法
  • 疾患の定義と診断
  • 患者区分
  • 国別治療ツリー
  • 現在の治療オプション
  • 処方動向
  • アンメットニーズ
  • 将来の治療法

疫学:慢性腎臓病による貧血

  • エグゼクティブサマリー
  • 情報源・調査手法
  • 予測
  • 疫学者による分析
  • 強み・制約

上市済み薬剤:慢性腎臓病による貧血

  • エグゼクティブサマリー
  • 製品概要
  • 製品プロファイル:Aranesp
  • 製品プロファイル:Epogen
  • 製品プロファイル:Mircera
  • 製品プロファイル:Triferic
  • 製品プロファイル:Venofer

パイプライン:慢性腎臓病による貧血

  • エグゼクティブサマリー
  • 臨床パイプラインの概要
  • 製品プロファイル (開発後期):Auryxia
  • 製品プロファイル (開発後期):Feraccru
  • 製品プロファイル (開発後期):roxadustat
目次
Product Code: DMKC13144

Overview

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Market Snapshot

  • The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
  • Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
  • By 2037, there will be an estimated 28% increase in total prevalent cases in the US, Japan, and five major EU markets.
  • Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
  • Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.

TABLE OF CONTENTS

FORECAST: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • PRODUCT PROFILE: ARANESP
  • PRODUCT PROFILE: AURYXIA
  • PRODUCT PROFILE: DEXFERRUM
  • PRODUCT PROFILE: EPOGEN
  • PRODUCT PROFILE (LATE STAGE): FERACCRU
  • PRODUCT PROFILE: FERAHEME
  • PRODUCT PROFILE: INJECTAFER
  • PRODUCT PROFILE: MIRCERA
  • PRODUCT PROFILE: NEORECORMON
  • PRODUCT PROFILE: VENOFER
  • PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

TREATMENT: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 09 March 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN ANEMIA IN CHRONIC KIDNEY DISEASE
  • FUTURE TREATMENT

EPIDEMIOLOGY: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 17 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY

MARKETED DRUGS: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ARANESP
  • PRODUCT PROFILE: AURYXIA
  • PRODUCT PROFILE: DEXFERRUM
  • PRODUCT PROFILE: EPOGEN
  • PRODUCT PROFILE: FERAHEME
  • PRODUCT PROFILE: INJECTAFER
  • PRODUCT PROFILE: MIRCERA
  • PRODUCT PROFILE: NEORECORMON
  • PRODUCT PROFILE: VENOFER

PIPELINE: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): FERACCRU
  • PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

LIST OF FIGURES

  • Figure 1: Anemia in chronic kidney disease - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for anemia in chronic kidney disease
  • Figure 3: Anemia in chronic kidney disease market sales across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 4: Sales of ESAs and roxadustat in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 5: Anemia in chronic kidney disease market sales in the US, Japan, and five major EU markets, by class, 2015-24
  • Figure 6: Sales of Epogen and biosimilar epoetin alfa in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 7: Sales of biosimilar epoetin alfa in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 8: Sales of iron supplements in anemia in chronic kidney disease in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 9: Patient-based forecast methodology for anemia in chronic kidney disease
  • Figure 10: Price sources and calculations, by country
  • Figure 11: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 14: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 18: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • Figure 20: Epogen for anemia in chronic kidney disease - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 23: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 24: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 27: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 28: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 29: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 32: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • Figure 33: Mircera for anemia in chronic kidney disease - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 36: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 37: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • Figure 38: Venofer for anemia in chronic kidney disease - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 41: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 42: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 44: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 45: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 46: Physician-estimated rate of diagnosis of anemia in chronic kidney disease, by country (%)
  • Figure 47: Proportion of anemia in chronic kidney disease patients at each grade of disease, by country (%)
  • Figure 48: Proportion of patients with anemia in chronic kidney disease receiving treatment from each physician type, by country (%)
  • Figure 49: Proportion of patients with mild anemia receiving each treatment type, by country (%)
  • Figure 50: Proportion of patients with moderate anemia receiving each treatment type, by country (%)
  • Figure 51: Proportion of patients with severe anemia receiving each treatment type, by country (%)
  • Figure 52: Proportion of patients with very severe anemia receiving each treatment type, by country (%)
  • Figure 53: Proportion of patients prescribed top five pharmacological treatments, by country (%)
  • Figure 54: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each ESA (alone or in combination), by country
  • Figure 55: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each iron supplement (alone or in combination), by country
  • Figure 56: Average length of iron supplement treatment, by anemia grade (days)
  • Figure 57: Expected epoetin alfa biosimilar use in new patients compared to physician-reported use in the 5EU and Japan, by country (%)
  • Figure 58: Expected epoetin alfa biosimilar use in patients currently receiving epoetin alfa compared to physician-reported use in the 5EU and Japan, by country (%)
  • Figure 59: Newly diagnosed patients expected to be prescribed an oral ESA, one and three years post-launch, by country (%)
  • Figure 60: Patients on stable ESA therapy expected to be switched to an oral ESA, one and three years post-launch, by country (%)
  • Figure 61: Trends in total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 62: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 65: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 66: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 69: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 70: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • Figure 71: Epogen for anemia in chronic kidney disease - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 74: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 75: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 76: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 79: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • Figure 80: Mircera for anemia in chronic kidney disease - SWOT analysis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 83: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

LIST OF TABLES

  • Figure 84: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • Figure 85: Venofer for anemia in chronic kidney disease - SWOT analysis
  • Figure 86: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 88: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 89: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • Figure 90: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 91: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 92: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 93: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • Figure 94: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 95: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 96: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare's anemia in chronic kidney disease patient-based forecast
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Hematologists and nephrologists surveyed for the anemia in chronic kidney disease primary research study, 2015
  • Table 4: Aranesp drug profile
  • Table 5: Aranesp pivotal trial data in anemia in chronic kidney disease
  • Table 6: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • Table 7: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 8: Auryxia drug profile
  • Table 9: Auryxia Phase III data in anemia in chronic kidney disease
  • Table 10: Auryxia Phase II data in anemia in chronic kidney disease
  • Table 11: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 12: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • Table 13: Epogen drug profile
  • Table 14: Epogen pivotal trial data in anemia in chronic kidney disease
  • Table 15: Epogen other late-phase trial data in anemia in chronic kidney disease
  • Table 16: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 17: Feraccru drug profile
  • Table 18: Feraccru Phase III trials in anemia in chronic kidney disease
  • Table 19: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 20: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 21: Injectafer drug profile
  • Table 22: Injectafer Phase III data in anemia in chronic kidney disease
  • Table 23: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • Table 24: Mircera drug profile
  • Table 25: Mircera pivotal trial data in anemia in chronic kidney disease
  • Table 26: Mircera late-phase trial data in anemia in chronic kidney disease
  • Table 27: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 28: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • Table 29: Venofer drug profile
  • Table 30: Venofer pivotal trial data in anemia in chronic kidney disease
  • Table 31: Venofer late-phase trial data in anemia in chronic kidney disease
  • Table 32: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 33: Roxadustat drug profile
  • Table 34: Roxadustat Phase III trials in anemia in chronic kidney disease
  • Table 35: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • Table 36: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 37: Nephrologists and hematologists surveyed for the anemia in chronic kidney disease primary research study, November 2015
  • Table 38: Grades of anemia in chronic kidney disease and corresponding hemoglobin levels
  • Table 39: Treatments available for anemia in chronic kidney disease across the US, Japan, and five major EU markets
  • Table 40: Definitions applied for anemia case ascertainment
  • Table 41: Definition applied for CKD case ascertainment and severity segmentation
  • Table 42: Sources used for the epidemiological analysis of anemia in CKD in the US, Japan, and five major EU markets, by country
  • Table 43: Total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 44: Key marketed drugs for anemia in chronic kidney disease
  • Table 45: Aranesp drug profile
  • Table 46: Aranesp pivotal trial data in anemia in chronic kidney disease
  • Table 47: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • Table 48: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 49: Auryxia drug profile
  • Table 50: Auryxia Phase III data in anemia in chronic kidney disease
  • Table 51: Auryxia Phase II data in anemia in chronic kidney disease
  • Table 52: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 53: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • Table 54: Epogen drug profile
  • Table 55: Epogen pivotal trial data in anemia in chronic kidney disease
  • Table 56: Epogen other late-phase trial data in anemia in chronic kidney disease
  • Table 57: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 58: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 59: Injectafer drug profile
  • Table 60: Injectafer Phase III data in anemia in chronic kidney disease
  • Table 61: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • Table 62: Mircera drug profile
  • Table 63: Mircera pivotal trial data in anemia in chronic kidney disease
  • Table 64: Mircera late-phase trial data in anemia in chronic kidney disease
  • Table 65: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 66: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • Table 67: Venofer drug profile
  • Table 68: Venofer pivotal trial data in anemia in chronic kidney disease
  • Table 69: Venofer late-phase trial data in anemia in chronic kidney disease
  • Table 70: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 71: Phase III pipeline products in development for anemia in chronic kidney disease
  • Table 72: Feraccru drug profile
  • Table 73: Feraccru Phase III trials in anemia in chronic kidney disease
  • Table 74: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 75: Roxadustat drug profile
  • Table 76: Roxadustat Phase III trials in anemia in chronic kidney disease
  • Table 77: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • Table 78: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24